Glaucoma laser treatment ready to go to trial

Article

Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.

Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.

The second-generation OT134 system is based on the company's smart laser-based technology known as LNPDS (CO2 Laser Non-Penetrating Deep Sclerectomy) that has already undergone successful testing on 23 patients in clinical trials. The OT134 upgrades have been designed to offer improved efficacy and ergonomics.

IOPtima plans to initiate a multinational, long-term, human clinical trial later this year.

Recent Videos
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
Abdelrahman Elhusseiny, MD, MSc, discusses his AAO presentation on risk of posterior capsular rupture in fellow-eyes cataract surgery
Related Content
© 2024 MJH Life Sciences

All rights reserved.